Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Kailera Therapeutics Plans IPO to Fund Obesity Pipeline After Burning Through USD 347M in Development Costs

Fineline Cube Mar 31, 2026
Company Deals

Biocytogen Licenses RenNano Antibody Platform to Japan’s Taisho Pharmaceutical in Strategic Partnership

Fineline Cube Mar 31, 2026
Company Deals

AIM Vaccine Plans Beijing Stock Exchange IPO to Strengthen Capital Base and Expand Operations

Fineline Cube Mar 31, 2026
Company Deals

Shaanxi Micot Files HKSE Listing Application to Advance Bifunctional Peptide Drug Pipeline

Fineline Cube Mar 31, 2026
Company Deals

Salubris Pharma Licenses Sintanovo’s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China

Fineline Cube Mar 30, 2026
Policy / Regulatory

NMPA Finalizes Conditional Drug Approval Framework to Accelerate Access to Critical Medicines

Fineline Cube Mar 31, 2026
Company Drug

Abbisko Therapeutics Secures FDA Clearance for ABSK061 Pediatric Achondroplasia Trial, Advancing Oral FGFR2/3 Inhibitor

Fineline Cube Mar 31, 2026
Company Drug

ImmuneOnco Doses First Patient in Phase III Trial of World’s First CD47/CD20 Bispecific for Follicular Lymphoma

Fineline Cube Mar 31, 2026
Company Drug

Luye Pharma’s Lurbinectedin Receives Hainan Approval for SCLC Treatment

Fineline Cube Jul 18, 2022

China-based Luye Pharma Group (HKG: 2186) announced approval from the Hainan Medical Products Administration for...

Company Drug

Novartis’ Aimovig Launches in China via GBA Early Access Scheme for Migraine Treatment

Fineline Cube Jul 15, 2022

Swiss pharma giant Novartis’ (NYSE: NVS) migraine therapy Aimovig (erenumab) was administered for the first...

Drug

CStone Pharmaceuticals’ Gavreto Wins Hong Kong Approval for RET Fusion NSCLC

Fineline Cube Jul 15, 2022

CStone Pharmaceuticals (HKG: 2616) announced that its RET inhibitor Gavreto (pralsetinib) has received marketing approval...

Company Medical Device

NMPA Approves RocketHeart’s LV Assist System and Our United Group’s Radiation Therapy Device

Fineline Cube Jul 15, 2022

The National Medical Products Administration (NMPA) has approved marketing for two innovative medical devices: RocketHeart’s...

Company Deals Digital

Ping An Good Doctor Partners with China Biotech Services for Cancer Testing and BNCT Treatment

Fineline Cube Jul 15, 2022

China-based Ping An Healthcare and Technology Co., Ltd (HKG: 1833), also known as PingAn Good...

Company Drug

Kelun Pharma’s SKB264 ADC Receives NMPA Green Light for Phase II Solid Tumor Study

Fineline Cube Jul 15, 2022

China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) announced that its antibody drug conjugate (ADC)...

Company Drug

Luye Pharma Initiates Phase III Study of Trulicity Biosimilar BA5101 in China

Fineline Cube Jul 15, 2022

China-based Luye Pharma Group (HKG: 2186) announced the initiation of a Phase III clinical study...

Company Deals

Shanghai Electric and Siemens Partner on Localization of High-End Medical Equipment

Fineline Cube Jul 15, 2022

China’s Shanghai Electric Group has partnered with Germany-based Siemens Healthineers to localize high-end medical equipment,...

Company Drug

Beijing Science Sun’s LZ901 Shingles Vaccine Receives FDA IND Approval

Fineline Cube Jul 15, 2022

China-based Beijing Science Sun Pharmaceutical Co., Ltd (SHE: 300485) announced that its subsidiary Beijing Luzhu...

Company Deals

Ningbo HicRen Biotech Completes RMB100M Pre-Series C Financing for Orthopedic Robots

Fineline Cube Jul 15, 2022

Ningbo HicRen Biotechnology Co., Ltd, a China-based robotics-driven minimally invasive orthopedics platform, announced the completion...

Company Deals

CStone Pharmaceuticals Explores Strategic Options Including Buyout

Fineline Cube Jul 15, 2022

China-based CStone Pharmaceuticals (HKG: 2616) is evaluating strategic options, including a potential buyout, according to...

Drug

BeiGene’s Tislelizumab Faces FDA Delay Due to Inspection Hurdles

Fineline Cube Jul 15, 2022

BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) announced a delay in the U.S. FDA’s decision...

Company Deals Drug

Frontier Biotech and Asymchem Partner on COVID-19 Drug FB2001 Development

Fineline Cube Jul 15, 2022

China-based Frontier Biotechnologies Inc. (SHE: 200342) announced a strategic partnership with Asymchem Laboratories (Tianjin) Co.,...

Company Medical Device

Acotec Scientific’s AcoArt Orchid & Dhalia DCB Wins China Approval for AVF PTA

Fineline Cube Jul 14, 2022

China-based Acotec Scientific Holdings Ltd (HKG: 6669) announced that its AcoArt Orchid & Dhalia DCB,...

Company Deals

Orion Holdings to Build Jining Vaccine Plant in China’s Shandong Province

Fineline Cube Jul 14, 2022

South Korea-based conglomerate Orion Holdings Corp. will enter China’s vaccine market by constructing a manufacturing...

Company Drug

Hangzhou DAC Biotech Doses First Patient in DXC007 AML Study

Fineline Cube Jul 14, 2022

China-based Hangzhou DAC Biotech Co., Ltd announced the first patient enrollment and dosing in a...

Company Deals

Shanghai Ark Bio Raises Series D Funding to Advance Pediatric and Respiratory Drug Pipeline

Fineline Cube Jul 14, 2022

China-based Shanghai Ark Biopharmaceutical Co., Ltd has completed a Series D financing round, following its...

Company Drug

Simcere’s Trilaciclib Wins NMPA Approval for Chemotherapy Myeloprotection

Fineline Cube Jul 14, 2022

Jiangsu Simcere Pharmaceutical Co., Ltd’s trilaciclib has received marketing approval from the National Medical Products...

Policy / Regulatory

China’s 2021 Healthcare Report Shows Rising Life Expectancy, Increased Medical Spending

Fineline Cube Jul 14, 2022

China’s National Health Commission (NHC) released the “Healthcare Statistical Communique 2021,” revealing increased healthcare spending,...

Company Deals

Sinopharm Biotec and Ganzhou Government Partner on Medical Testing and Biotech R&D

Fineline Cube Jul 14, 2022

Sinopharm China National Biotec Group Co., Ltd (CNBG) announced a strategic partnership with the government...

Posts pagination

1 … 627 628 629 … 644

Recent updates

  • Kailera Therapeutics Plans IPO to Fund Obesity Pipeline After Burning Through USD 347M in Development Costs
  • Abbisko Therapeutics Secures FDA Clearance for ABSK061 Pediatric Achondroplasia Trial, Advancing Oral FGFR2/3 Inhibitor
  • Luye Pharma Reports 31.1% Profit Surge Driven by New Product Growth and Oncology/CNS Segment Strength
  • Luye Pharma Subsidiary Boan Bio Reports 8.1% Revenue Growth Driven by Multiple Product Approvals in 2025
  • ImmuneOnco Doses First Patient in Phase III Trial of World’s First CD47/CD20 Bispecific for Follicular Lymphoma
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Kailera Therapeutics Plans IPO to Fund Obesity Pipeline After Burning Through USD 347M in Development Costs

Company Drug

Abbisko Therapeutics Secures FDA Clearance for ABSK061 Pediatric Achondroplasia Trial, Advancing Oral FGFR2/3 Inhibitor

Company

Luye Pharma Reports 31.1% Profit Surge Driven by New Product Growth and Oncology/CNS Segment Strength

Company

Luye Pharma Subsidiary Boan Bio Reports 8.1% Revenue Growth Driven by Multiple Product Approvals in 2025

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.